Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on September 2, 2021. The filing reports a regulatory milestone regarding the Company's product pipeline rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
The material event reported is the acknowledgment by the U.S. Food and Drug Administration (FDA) of the receipt of a supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules). The application seeks approval for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed.
Guidance, Outlook, and Risks
- Regulatory Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 29, 2022, for the review of the sNDA.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) but does not include additional management commentary, financial guidance, or specific risk factors within the body of this 8-K.
Investor Verification Checklist
- Verify the PDUFA date of April 29, 2022, for the Qelbree adult ADHD sNDA.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical data supporting the adult indication.
- Monitor future filings for the FDA's final decision on the sNDA prior to the PDUFA date.
- Check subsequent quarterly reports (10-Q) for any financial impact related to the potential expansion of the Qelbree market.